Tiziana Life Sciences announces study results on foralumab published

Tiziana Life Sciences announced that a study related to its lead candidate, foralumab, was highlighted in Neurology Today, the official news source of the American Academy of Neurology, in an article titled, “Anti-CD3 Antibody Foralumab Shows Promise in PIRA, Measured by Novel PET Ligand.” The study shows that foralumab, a fully human anti-CD3 monoclonal-antibody, attenuates microglial activation in non-active secondary progressive multiple sclerosis patients with progression independent of relapse. A systemic review published in JAMA Neurology in October 2023 found that PIRA is the most frequent manifestation of disability accumulation across the full spectrum of traditional multiple sclerosis phenotypes. The study assesses the effect of intranasal foralumab on microglial activation in na-SPMS patients with PIRA as measured by positron emission tomography imaging via radiology marker (F-18)PBR06-PET, a novel, long-half-life ligand used in PET scanning. The study is designed to be open-label and is based on data from the Expanded-Access Program evaluating foralumab in na-SPMS patients that is currently underway. In this study, five of six patients showed a qualitative reduction on PBR06-PET in multiple brain regions after both 3 and 6 months of nasal foralumab treatment.